Zenlabs Ethica Limited (ZENLABS.BO)
BSE · INR · Healthcare · Medical Distribution
₹26.60 (-1.12%) as of
Key statistics
- Market cap
- 173.17M
- EPS (TTM)
- -3.90
- Dividend yield
- 0.00%
- 52-week range
- 16.50 – 39.99
- Beta
- 0.17
- Revenue (TTM)
- 496.22M
- Profit margin
- -5.12%
- Volume
- 1.03k
About Zenlabs Ethica Limited
Zenlabs Ethica Limited markets and distributes pharmaceutical products in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. In addition, it provides its products under the RBC Red Super Active and Zenovit brands. The company serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, and Bangladesh. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016. Zenlabs Ethica Limited was incorporated in 1993 and is headquartered in Chandigarh, India.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Headquarters
- Chandigarh, India
- Employees
- 66
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.